Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
CDMO will exit clinical packaging and semisolids, expand PDS, establish CoE commercial network
September 9, 2011
By: Gil Roth
President, Pharma & Biopharma Outsourcing Association
Following a company-wide review, Patheon will launch a new corporate strategy, exiting clinical packaging and semisolid manufacturing, optimizing the CMO network, and focusing on development services. In a press statement, Patheon’s chief executive officer, James Mullen, said, “We will create the premier, customer-focused, contract pharmaceutical development and manufacturing organization in the world. This should enable attractive earnings and cash flow to reinvest in the business and grow over the long-term.” As part of the initiative, Patheon will look for a buyer for its Swindon, UK commercial operations. During the quarterly earnings conference call in which the new strategy was unveiled, Mr. Mullen, noted that the company had received interest in Swindon’s cephalosporins business. He noted that the site’s sterile fill operations could be better conducted at one of Patheon’s two sites in Italy, and that the site’s development services business will be retained. The company also plans to consolidate QC operations at its Burlington, Ontario site into its Toronto site, but has not fielded any offers for a sell-off or spin-out for the site’s clinical packaging operations. Regarding the decision to exit clinical packaging, Mr. Mullen remarked, “Competitors’ moves in that space have made them larger and larger. We’re not in a position to compete without making a large acquisition, and I don’t believe that’s a good idea in the near term.” Patheon will focus on expanding its commercial operations through a Centers of Excellence (CoE) transformation. With its remaining network, Patheon plans to operate its sites as six CoEs, with four focused on solids and two on steriles. “We can substantially increase revenues in the network through the facilities we have, even after exiting Swindon,” Mr. Mullen commented. Mr. Mullen remarked that the market for commodity contract manufacturing officers is stagnant, but rebuffed an analyst’s question about a potential merger or acquisition for Patheon, commenting, “We don’t agree that the CMO market is contracting. I don’t think it’s growing at rapid rate, but I think it’s growing in mid-single-digits.” The company will also dedicate resources to improving its Pharmaceutical Development Services (PDS) business. In the earnings call, Mr. Mullen noted that nearly 20% of Patheon’s commercial manufacturing business resulted from PDS relationships. He added that PDS revenues were expected to climb, even as R&D budgets shrink overall. Patheon plans to expand PDS into Early Development services, beginning with a new facility in San Francisco that is scheduled to launch in October. Previously, Patheon had announced plans to move its European HQ from Zug, Switzerland to the UK and to transfer operations from its Caguas, PR facility to Manati, PR. The cost of the new moves was not provided. Eric Evans, Patheon’s chief financial officer, said in the earnings call that the cost of implementation would be “cash-neutral at the beginning, with a one- or two-quarter lag.” Consulting for the review, including operational consultants on the production floor, cost $2.4 million in 3Q11.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !